MIRCERA.com

MIRCERA administered subcutaneously (SC) or intravenously (IV) provides haemoglobin (Hb) stability during maintenance therapy with once-monthly dosing.^1–8  Once-monthly MIRCERA keeps average Hb levels within a range of 11–12 g/dL during maintenance therapy (see Figure).^2,4,5–8

 

 

Mean haemoglobin (Hb) levels during maintenance therapy in patients receiving once-monthly intravenous (IV) or subcutaneous (SC) MIRCERA.^2,4,5–8

 

References:

 

1. Levin NW, Imbasciati E, Combe C, et al. Adequate Hb levels are maintained with IV C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in dialysis patients irrespective of age, gender or diabetic status. J Am Soc Nephrol. 2006;17:619A (abstract SA-PO206).
2. Ryckelynck J-P, Harris K, Selga R, et al. SC C.E.R.A. (continuous erythropoietin receptor activator) administered up to once monthly in patients with CKD on dialysis maintains adequate Hb levels regardless of age, gender or diabetic status. J Am Soc Nephrol. 2006;17:620A (abstract SA-PO210).
3. Imbasciati E, Bernado M, Caraman P-L, et al. Stable haemoglobin (Hb) levels are maintained with once-monthly C.E.R.A. in dialysis with varying C-reactive protein (CRP), albumin or dialysis adequacy. Nephrol Dial Transplant. 2007 In Press (abstract Suo005).
4. Mann J, Locatelli F, Sulowicz W, et al. C.E.R.A. provides stable haemoglobin (Hb) levels in CKD patients on dialysis with and without coronary artery disease (CAD) or diabetes mellitus (DM) when administered once monthly. Presentation at European Renal Association – European Dialysis and Transplant Association XLIV Congress, Barcelona, Spain. 21–24 June 2007 (Abstract SuO002).
5. Sulowicz W, Locatelli F, Ryckelynck J-P, et al. Once-monthly subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) maintains stable control in patients with chronic kidney disease on dialysis directly converted from epoetin one to three times weekly. Clin J Amer Soc Nephrol. 2007 doi:10.2215/CJN.03631006.
6. Canaud B, Mingardi G, Braun J, et al., on behalf of the ARCTOS Study Investigators.  Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin: results from STRIATA, a randomized phase III study. 2007 Submitted.
7. Locatelli F, Sulowicz W, Harris K, et al.SC C.E.R.A. (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1–3 times per week in patients with CKD on dialysis. J Am Soc Nephrol 2006;17:619A.
8. Fishbane S, Levin NW, Mann JFE, et al. IV C.E.R.A. (continuous erythropoietin receptor activator) once every 2 weeks or once monthly maintains stable Hb levels after converting directly from IV epoetin 1–3 times per week in patients with CKD on dialysis. J Am Soc Nephrol 2006;17:618A (abstract SA-PO205).